anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Premenopausal women with ER-positive breast cancer treated by surgery and receiving postoperative tamoxifen with or without LHRH analogues, who may have received pre or postoperative chemotherapy, or immunotherapy (for HER2-positive disease), are recruited to a double-blind randomized clinical trial, to receive either a dry extract of red clover (Promensil) as one tablet/day orally containing 80 mg isoflavones (treatment group), or one oral tablet/day without active principle (placebo group) for 24 months. All patients receive a diet-lifestyle intervention involving meetings with a dietician (physician) scheduled once a month for the first 6 months, and every 3 months thereafter. The dietician encourages patients to adhere to a macronutrient-balanced, low glycaemic load Mediterranean-type diet with personalized recommendations to increase intakes of unrefined cereals, pulses, vegetables, unrefined vegetable fats (e.g. olive oil, nuts, oil-containing seeds), and fish, and reduce intake of high-glycaemic-index foods and saturated animal fats. Patients are also encouraged to undertake regular physical activity. Outcomes are Menopausal Rating Score (MRS), body mass index (BMI), waist and hip girth, insulin resistance, and levels of cholesterol, triglycerides, and sex hormones.

The safety of the red clover preparation is assessed by pelvic ultrasound and mammograms for endometrial thickness and breast density, and by evaluation of the effects of the serum from treated and placebo patients on ER-positive BC cell lines.
The deubiquitinating enzyme CYLD negatively regulates NF-κB signaling by removing activating ubiquitin chains from several members of the NF-κB pathway. Thereby, CYLD is critical for the maintenance and differentiation of various immune cells. Despite the importance of the NF-κB pathway in microglia regulation, the role of CYLD in microglia has not been investigated so far. In this study, we investigated whether CYLD in microglia can protect against neuroinflammation using a newly generated conditional mouse strain (Rosa26-Cyld-tdTomato) that allows cell type-specific CYLD overexpression. Here, we show that overexpression of CYLD in microglia did not alter microglia numbers or microglia morphology in different brain regions. Additionally, CYLD overexpression did not modify the microglial response to LPS-induced neuroinflammation or the disease severity in experimental autoimmune encephalomyelitis (EAE). Finally, also immune cell infiltration into the CNS during EAE and under steady state conditions remained unaffected by microglial CYLD overexpression. Our findings suggest that CYLD overexpression does not alter microglial function, and thus does not represent a viable therapeutic strategy in neuroinflammatory conditions. This study highlights the complexity of ubiquitin-mediated signaling in neuroinflammation and the need for cell-type-specific investigations. The Rosa26-Cyld-tdTomato mouse model offers a valuable tool for studying CYLD's role across various tissues and cell types. KEY MESSAGES: Novel mouse strain for cell type-specific overexpression of the deubiquitinating enzyme CYLD. CYLD overexpression in microglia did not alter microglia numbers or morphology in the steady state. CYLD overexpression in microglia did not protect mice from LPS-induced neuroinflammation or EAE. CYLD overexpression in microglia did not influence their gene expression during neuroinflammation.
People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP is a sterile aqueous suspension containing betamethasone 3 mg per milliliter as betamethasone sodium phosphate, and betamethasone acetate 3 mg per milliliter. Inactive ingredients per mL: dibasic sodium phosphate 7.1 mg; monobasic sodium phosphate 3.4 mg; edetate disodium 0.1 mg; and benzalkonium chloride 0.2 mg as a preservative. The pH is adjusted to between 6.8 and 7.2. 

The formula for betamethasone sodium phosphate is C 22H 28FNa 2O 8P and it has a molecular weight of 516.40. Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate). 

The formula for betamethasone acetate is C 24H 31FO 6 and it has a molecular weight of 434.50. Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-acetate. 

The chemical structures for betamethasone sodium phosphate and betamethasone acetate are as follows: 

Betamethasone sodium phosphate is a white to practically white, odorless powder, and is hygroscopic. It is freely soluble in water and in methanol, but is practically insoluble in acetone and in chloroform. 

Betamethasone acetate is a white to creamy white, odorless powder that sinters and resolidifies at about 165ºC, and remelts at about 200ºC to 220ºC with decomposition. It is practically insoluble in water, but freely soluble in acetone, and is soluble in alcohol and in chloroform.
PURPOSE:To classify and identify easily and exactly the prostate cancer from urine and tissue slice by using a reagent contg. the antibody (marked antibody) secreted from the hybridoma (syncytium) of antihuman prostate cancer antibody producing cells and cells which can be subcultured in vitro for a long period of time. CONSTITUTION:The antibody producing cells for a human prostate cancer cell strain 8PC93 are obtd. from the pulpar cells obtd. by immunizing a mouse, etc. with 8PC93. The syncytium of such cells and the myeloma cells, etc. that can be subcultured for a long period of time is obtd. and the antibody secreted from the syncytium is marked with a radioactive material, fluorescent dye, enzyme, etc. The antibody or marked antibody and the urine or tissue slice of a person to be examined are brought into reaction and the activity in marking or the like of the conjugate with the prostate cancer cells is measured. The identification and classification of the prostate cancer cells are thus specifically made possible with high accuracy and the discrimination from the other cancer and tumor is quickly performed.
BACKGROUND: Prognostic models that identify individuals with chronic kidney disease (CKD) at greatest risk of developing kidney failure help clinicians to make decisions and deliver precision medicine. It is recognised that people with CKD usually have multiple long-term health conditions (multimorbidity) and often experience frailty. We undertook a systematic review to evaluate the representation and consideration of multimorbidity and frailty within CKD cohorts used to develop and/or validate prognostic models assessing the risk of kidney failure.
METHODS: We identified studies that described derivation, validation or update of kidney failure prognostic models in MEDLINE, CINAHL Plus and the Cochrane Library-CENTRAL. The primary outcome was representation of multimorbidity or frailty. The secondary outcome was predictive accuracy of identified models in relation to presence of multimorbidity or frailty.
RESULTS: Ninety-seven studies reporting 121 different kidney failure prognostic models were identified. Two studies reported prevalence of multimorbidity and a single study reported prevalence of frailty. The rates of specific comorbidities were reported in a greater proportion of studies: 67.0% reported baseline data on diabetes, 54.6% reported hypertension and 39.2% reported cardiovascular disease. No studies included frailty in model development, and only one study considered multimorbidity as a predictor variable. No studies assessed model performance in populations in relation to multimorbidity. A single study assessed associations between frailty and the risks of kidney failure and death.
CONCLUSIONS: There is a paucity of kidney failure risk prediction models that consider the impact of multimorbidity and/or frailty, resulting in a lack of clear evidence-based practice for multimorbid or frail individuals. These knowledge gaps should be explored to help clinicians know whether these models can be used for CKD patients who experience multimorbidity and/or frailty.
SYSTEMATIC REVIEW REGISTRATION: This review has been registered on PROSPERO (CRD42022347295).
IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
In Slovenia, all children with cerebral palsy born in 1996 or later are included in the Slovenian National Registry of Cerebral Palsy. All patients from the Registry will be invited to participate in the study.
Studies have shown that frailty increases cardiovascular disease (CVD) incidence in older patients and is associated with poor patient prognosis. However, the relationship between medication deviation (MD) and frailty remains unclear. This study aimed to explore the influence of frailty on MD during the hospital-family transition period among older patients with CVD. Between February 2022 and February 2023, 231 older people CVD patients were selected from a class III hospital in Nantong City using a multi-stage sampling method. A general information questionnaire was used to collect the socio-demographic characteristics of the participants prior to discharge, the frailty assessment scale was used to assess the participants frailty, and a medication deviation instrument was used to assess the participants MD on the 10th day after discharge. Propensity score matching was used to examine the effect of frailty on MD in older patients with CVD during the hospital-family transition period. The incidences of frailty and MD were 32.9% (76/231) and 75.8% (175/231), respectively. After propensity score matching, the risk of MD in frail patients with CVD was 4.978 times higher than that in non-frail patients with CVD (95% CI: [1.616, 15.340]; P = .005). Incidences of frailty and MD during the hospital-family transition period are high in older patients with CVD, and frailty has an impact on MD. Medical staff in the ward should comprehensively examine older patients with CVD for frailty and actively promote quality medication management during the hospital-family transition period to reduce MD occurrence and delay disease progression.
MR examinations were performed by using the 3 Tesla unit (Siemens Magnetom Verio, Siemens Medical Solutions) with a dedicated eight-channel neurovascular phased array coil. The field of view was adjusted to include the area from the angle of the mandible to the level of the tracheal carina. The protocol included an axial and a coronal T1-weighted fast spin-echo (FSE) sequence, an axial T2-weighted FSE sequence with Dixon fat saturation, and a coronal and sagittal T2-weighted FSE sequence with inversion recovery fat saturation.

4DCT images were scanned with the 128-section dual-source multi-detector row unit (Somatom Definition Flash; Siemens Medical Solutions). All patients were scanned from the angle of the mandible to the carina. The 4DCT protocol included the acquisition of unenhanced images followed by the acquisition of arterial and delayed (venous) phase image series. Unenhanced images were obtained by using the following parameters: a collimation of 64×0.6 mm, 120 kVp for the deliverance of a dose-modulated amperage of 250 mAs, a pitch of 0.7, and a gantry rotation time of 0.28 seconds. The arterial and venous phase scans was performed in dual-energy mode with a dual source of 80 kVp and 140 kVp tube voltages using the following parameters: tube current-time product 230 and 89 mAs, respectively; collimation, 64 × 0.6 mm; rotation speed, 0.28 seconds; and helical pitch, 0.7. The arterial and venous phase scanning began automatically at 10 s and 35 s after the left common carotid artery reached the trigger attenuation threshold (100 HU) using automated scan-triggering software (CARE Bolus CT; Siemens Healthineers). The volume of iodinated contrast material (iohexol, Omnipaque 300; GE Healthcare, SH, China) was 70 mL, and the injection rate was 3 mL/s. The mean dual-source CT dose index volume was 34.5 mGy.

The sensitivity and specificity as well as the positive-predictive and negative-predictive values (PPV, NPV) of each imaging modality for preoperative parathyroid hyperplasia localization to the correct quadrant were compared. For the per-quadrant localization, if a lesion was suspected to be parathyroid hyperplasia by the imaging report and was correlated with the surgical and pathology results, this was interpreted as a true-positive lesion. Otherwise, if the lesion was not confirmed to be parathyroid hyperplasia during surgery, this was considered to be a false-positive case. If a lesion was not reported by the radiologist in the exact quadrant but was present during surgery and histopathologic examination, this was regarded as a false-negative lesion.
The usual dose of ketoprofen immediate-release capsules recommended for mild to moderate pain and dysmenorrhea is 25 to 50 mg every 6 to 8 hours as necessary. A smaller dose should be utilized initially in small individuals, in debilitated or elderly patients, or in patients with renal or liver disease (see PRECAUTIONS: General). A larger dose may be tried if the patient's response to a previous dose was less than satisfactory, but doses above 75 mg have not been shown to give added analgesia. Daily doses above 300 mg are not recommended because they have not been adequately studied. Because of its typical non-steroidal anti-inflammatory drug-side effect profile, including as its principal adverse effect GI side effects (see WARNINGS and ADVERSE REACTIONS), higher doses of ketoprofen immediate-release capsules should be used with caution and patients receiving them observed carefully.

Ketoprofen extended-release capsules are not recommended for use in treating acute pain because of its extended-release characteristics.
Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
The invention discloses an umbilical therapy formula for strengthening spleen, dehumidifying, slimming and fat reducing, which comprises the following raw materials in parts by weight: 10 parts of Chinese yam, 15 parts of poria cocos, 15 parts of Polyporus umbellatus, 10 parts of rhizoma atractylodis, 10 parts of bighead atractylodes rhizome, 10 parts of magnolia officinalis, 10 parts of lotus leaf, 5 parts of coptis chinensis, 5 parts of cortex phellodendri, and 10 parts of rhizoma pinellinae praeparata. The preparation method comprises the following steps: cleaning rhizoma Dioscoreae, poria and Polyporus, soaking for 2 hr, taking out, draining, and grinding into slurry; placing the slurry into an iron pan, and stir-frying until syrup appears; taking the seven medicinal powders after the formulation, and fully stirring; is put into a glass bottle for standby. The invention has the following beneficial effects: 1. the umbilical region is convenient to administer and operate, does not affect normal work and life 2. The umbilical region is a shenque acupoint, and the medicine is easy to penetrate and absorb and can enter blood circulation rapidly. 3. The umbilical administration can reduce the irritation of the medicine to gastrointestinal tract and reduce the influence of the medicine to liver and kidney functions.
With another formulation of bromocriptine mesylate, the most commonly reported signs and symptoms associated with acute overdose were nausea, vomiting, constipation, diaphoresis, dizziness, pallor, severe hypotension, malaise, confusion, lethargy, drowsiness, delusions, hallucinations, and repetitive yawning. The lethal dose has not been established.

Treatment of overdose consists of removal of the drug by emesis (if conscious), gastric lavage, activated charcoal, or saline catharsis. Careful supervision and recording of fluid intake and output is essential. Hypotension should be treated by placing the patient in the Trendelenburg position and administering intravenous fluids. If satisfactory relief of hypotension cannot be achieved by using the above measures to their fullest extent, vasopressors should be considered.
A cosmetic composition for temporarily reshaping keratin fibres, comprising at least one cationically modified guar derivative with a weight-average molecular weight in the range of 5,000-200,000 and a degree of cationic substitution in the range of from 0.1-2; and at least one cationic vinylcaprolactam-containing copolymer. Preferably, the guar derivative is guar hydroxypropyltrimonium chloride. The cationic vinylcaprolactam copolymer may be a copolymer comprising a vinylcaprolactam unit, a vinylpyrrolidone unit, a dialkylaminoalkyl (meth)acrylamide unit and a (meth)acryloylaminoalkyl-trialkylammonium chloride unit, most preferably, polyquaternium-69. The composition may also comprise an alkanolamine. The use of the cosmetic composition for the temporary reshaping of keratin fibres is disclosed, as is a method for temporarily reshaping keratinous fibres, in which the cosmetic composition is applied to the keratin fibres, preferably hair, and the form of the fibres is fixed. The cosmetic composition aims to provide a styling agent with long-term hold and high curl retention in humid conditions.
Participants in this group will receive care guided by the impairments identified with the KneeKG. The KneeKG exam results in recommended exercises that target the specific biomechanical impairments identified. The exercises and dose given to the participant will be based on what the KneeKG device recommends after the exam. The participant will be seen twice a week for 4 weeks.
Lotensin can cause symptomatic hypotension. Like other ACE inhibitors, benazepril has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume-and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Volume-and/or salt-depletion should be corrected before initiating therapy with Lotensin.

In patients with congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension, which may be associated with oliguria or azotemia and, rarely, with acute renal failure and death. In such patients, Lotensin therapy should be started under close medical supervision; they should be followed closely for the first 2 weeks of treatment and whenever the dose of benazepril or diuretic is increased.

If hypotension occurs, the patient should be placed in a supine position, and, if necessary, treated with intravenous infusion of physiological saline. Lotensin treatment usually can be continued following restoration of blood pressure and volume.
Participants will receive Active tDCS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
The endodontic pin for introducing into a curved root canal with a single-piece base body (1), comprises a plastic matrix (2), which is reinforced with fibers (3) that are embedded parallel to a longitudinal axis in the plastic matrix. The base body has zones with different flexural and torsional strengths, where one zone has a reduced flexural and torsional strength. The plastic matrix reinforced with the fibers contains different concentrations of reflection-/absorption particles over a length and a cross-section of the base body for reflecting and absorbing a laser beam (11). The endodontic pin for introducing into a curved root canal with a single-piece base body (1), comprises a plastic matrix (2), which is reinforced with fibers (3) that are embedded parallel to a longitudinal axis in the plastic matrix. The base body has zones with different flexural and torsional strengths, where one zone has a reduced flexural and torsional strength. The plastic matrix reinforced with the fibers contains different concentrations of reflection-/absorption particles over a length and a cross-section of the base body for reflecting and absorbing a laser beam (11), so that the different bending and torsional stiffnesses are obtained. A higher portion of the reflection-/absorption particles is contained in one zone having high flexural and torsional strength than in one zone having reduced flexural and torsional strength. The outer surfaces of the pin have displacement elements in the form of channels and/or grooves. The displacement elements axially or arcuately run to the longitudinal axis. The reflection-/absorption particles are contained in a concentration of 1-90 wt.%, and have a diameter of 10-100 nm. The reinforced fibers are organic and/or mineralized fibers, which are contained in a concentration of 50-90 wt.%. The endodontic pin has a filler material, which is contained in the plastic matrix with a portion of 50-90 wt.%. The base body has two zones with increased flexural and torsional strength in dependent of its lengths, a conically running distal tip area (8), in which externally-lying fiber ends are remelted from the plastic matrix and which has a structure module of 3-15 GPa, a proximal end, which has a structure module of 15-50 GPa, and a constriction. An independent claim is included for a method for producing an endodontic pin.
Treatment As Usual control group receives the standard intervention for bariatric surgery offered by multidisciplinary teams in Portuguese public hospitals. It consists of endocrinology, nutrition and surgery consultations, usually lasting 30 minutes every 6 months. These consultations usually include a physical exam (weight, height) and personalized diet/lifestyle recommendations. The Treatment as usual intervention is common to the Apolo_Bari Steppped-care intervention group and the treatment as usual control groups.
Apply Eucerin Healing Lotion (mineral oil (occlusive) and sorbitol/propylene glycol (humecants)) followed by metronidazole cream. Tape striping will occur at 1 hours and 4 hours post metronidazole application.
PWT1D participants will have access to Support, independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada.
Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m\^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.